Quantcast
Channel: chronic obstructive pulmonary disease – BioTuesdays
Browsing latest articles
Browse All 7 View Live

Image may be NSFW.
Clik here to view.

Aquinox sitting pretty ahead of Phase 2a data

With a strong investor syndicate of venture capital funds, closely held Aquinox Pharmaceuticals of Vancouver is in an enviable position ahead of the release, in June, of Phase 2a clinical trial results...

View Article



Image may be NSFW.
Clik here to view.

Brainsway reports positive smoking cessation results

Brainsway (TASE:BRIN) has reported additional positive final results in a clinical trial at Israel’s Be’er Ya’akov Mental Health Center to assess the efficacy of its Deep TMS device in inducing smoking...

View Article

Image may be NSFW.
Clik here to view.

In conversation with Bing Yao

Bing Yao As an SVP of AstraZeneca’s (NYSE:AZN) MedImmune unit, Bing Yao heads the Respiratory, Inflammation & Autoimmunity (RIA) Innovative Medicines unit at MedImmune, leading a team dedicated to...

View Article

Image may be NSFW.
Clik here to view.

Inogen POCs represent paradigm shift in oxygen therapy

Inogen (NASDAQ:INGN) is continuing to convert patients with lung disease from bulky oxygen tanks that need to be refilled every two weeks to its lightweight, portable oxygen concentrator (POC) that...

View Article

Image may be NSFW.
Clik here to view.

MediciNova to release asthma and COPD trial results in Q2

MediciNova (NASDAQ:MNOV; OSE:4875) expects to release results from two clinical trials in the current second quarter with its lead drug candidate, MN-221, opening the door to a possible pivotal trial....

View Article


Image may be NSFW.
Clik here to view.

Leerink starts Theravance Biopharma at outperform

Leerink has initiated coverage of Theravance Biopharma (NASDAQ:TBPH) with an “outperform” rating and $26 price target. The stock closed at $18.10 on Wednesday. Theravance was formed in 2014 via a spin...

View Article

Image may be NSFW.
Clik here to view.

HCW starts Aviragen Therapeutics at buy

H.C. Wainwright launched coverage of Aviragen Therapeutics (NASDAQ:AVIR) with a “buy” rating and price target of $5. The stock closed at $1.43 on Tuesday. Aviragen is a developing three direct-acting...

View Article
Browsing latest articles
Browse All 7 View Live




Latest Images